In short
There is currently 1 ongoing clinical trial focused on testicular seminoma (pure) stage II. This trial is investigating a reduced intensity treatment approach combining chemotherapy and radiotherapy for patients with stage IIA/B seminoma, conducted in Germany.
Clinical trial locations
Study on Reduced Intensity Radio-Chemotherapy for Stage IIA/B Seminoma Using Etoposide, Cisplatin, and Carboplatin for Patients with Stage IIA/B Seminoma
This clinical trial is exploring a treatment approach that combines reduced intensity chemotherapy and radiotherapy for patients with stage IIA or IIB seminoma, a type of testicular cancer. The study is being conducted in Germany and aims to determine how effective this treatment combination is in preventing cancer progression.
Main inclusion criteria:
- You must be at least 18 years old
- You need a confirmed diagnosis of classical seminoma that has been treated with surgery
- Your cancer must be stage IIA or IIB, either newly diagnosed or recurring after previous treatments
- You must have had recent imaging scans (CT, MRI, or FDG-PET-CT) within 28 days before joining
- Your kidneys must be functioning well, with a creatinine clearance of at least 60 ml/min
- Your bone marrow must be working properly, with adequate blood cell counts
- Your ability to carry out daily activities should be good, with a WHO performance status between 0 and 2
- You must agree to use effective contraception during the study and for 12 months after, and should consider sperm preservation
- You need to provide written informed consent after understanding all details of the study
Main exclusion criteria:
- Only males can participate in this trial
- Individuals without stage IIA/B seminoma cannot join
- Those outside the specified age range are excluded
- Vulnerable populations who may not be able to give informed consent are not eligible
Trial focus and goals:
The study investigates whether a reduced intensity treatment approach can effectively control stage IIA/B seminoma. The main goal is to assess how long patients remain free from cancer progression over a three-year period. Researchers will also evaluate the response rate to treatment, time to cancer progression, and overall survival rates. Throughout the trial, participants undergo regular health assessments including imaging tests to monitor the cancer's status.
Investigational drugs:
The treatment involves three chemotherapy medications given through intravenous infusion:
- Etoposide – administered as part of the chemotherapy regimen
- Cisplatin – a platinum-based drug that works by damaging cancer cell DNA, preventing them from dividing and growing
- Carboplatin – another chemotherapy medication that interferes with cancer cell DNA to reduce tumor size and stop cancer spread
In addition to chemotherapy, radiotherapy is used alongside the medications to enhance treatment effectiveness. Radiotherapy uses high-energy rays to target and kill cancer cells while minimizing damage to healthy surrounding tissue.
The treatment schedule and dosage are tailored to each patient's specific needs and cancer stage. The trial is estimated to conclude by March 31, 2045, after which results will be analyzed to determine the effectiveness of this reduced intensity treatment approach.
Summary
Currently, there is one active clinical trial for testicular seminoma (pure) stage II, specifically focusing on stage IIA/B disease. This trial is being conducted in Germany and represents an important investigation into alternative treatment approaches for this condition. The study explores whether combining reduced intensity chemotherapy using three established cancer drugs—etoposide, cisplatin, and carboplatin—with radiotherapy can effectively control cancer progression while potentially reducing treatment intensity.
The trial focuses on male patients with confirmed stage IIA or IIB seminoma, whether newly diagnosed or recurring after previous treatments. With an estimated completion date extending to 2045, this long-term study will provide valuable information about progression-free survival rates over three years and overall treatment outcomes. Patients interested in participating should discuss eligibility requirements with their healthcare provider, particularly regarding kidney function, blood cell counts, and the need for contraception and sperm preservation during and after treatment.
